CLAIMS

1. A pharmaceutical composition comprising a *Clostridium botulinum* toxin Type A complex and a pharmaceutically or dermatologically acceptable carrier, wherein the *Clostridium botulinum* toxin Type A complex comprises a HA70 component, a HA17 component, a HA33 component, a NTNH component and a BoNT/A1 component; wherein

(1) the HA70 component comprises the amino acid sequence of SEQ ID NO. 1 with retaining the function of the HA70 component;

(2) the HA17 component comprises the amino acid sequence of SEQ ID NO. 2 with retaining the function of the HA17 component;

(3) the HA33 component comprises

the amino acid sequence of SEQ ID NO. 3 with retaining the function of the HA33 component;

(4) the NTNH component comprises

the amino acid sequence of SEQ ID NO. 4 with retaining the function of the NTNH component;

(5) wherein the BoNT/A1 component comprises

the amino acid sequence of SEQ ID NO. 5 with retaining the function of the BoNT/A1 component; and

wherein the *Clostridium botulinum* toxin Type A complex has a molecular weight of 740-790 kDa.

2. A liquid formulation comprising a *Clostridium botulinum* toxin Type A complex, wherein the *Clostridium botulinum* toxin Type A complex comprises a HA70 component, a HA17 component, a HA33 component, a NTNH component and a BoNT/A1 component; wherein

(1) the HA70 component comprises the amino acid sequence of SEQ ID NO. 1 with retaining the function of the HA70 component;

(2) the HA17 component comprises the amino acid sequence of SEQ ID NO. 2 with retaining the function of the HA17 component;

(3) the HA33 component comprises the amino acid sequence of SEQ ID NO. 3 with retaining the function of the HA33 component;

(4) the NTNH component comprises the amino acid sequence of SEQ ID NO. 4 with retaining the function of the NTNH component;

(5) wherein the BoNT/A1 component comprises the amino acid sequence of SEQ ID NO. 5 with retaining the function of the BoNT/A1 component; and

wherein the *Clostridium botulinum* toxin Type A complex has a molecular weight of 740-790 kDa.

3. The liquid formulation of claim 2, comprising human serum albumin, methionine, arginine, sodium chloride, Tween 80, citrate buffer, and/or phosphate buffer.

4. The pharmaceutical composition of claim 1, or the liquid formulation of claim 2 or 3, for use in treating or preventing a disease.

5. An aesthetic method comprising administering an effective amount of the liquid formulation of claim 2 or 3 to a subject in need thereof.

6. The aesthetic method of claim 5, comprising reducing the appearance of fine lines and/or wrinkles, enlarging eyes, lifting the corners of mouth, smoothing lines that appear on the upper lip, or relieving muscle tone.

7. Use of the pharmaceutical composition of claim 1 or the liquid formulation of claim 2 or 3 in the preparation of a medicament for treating or preventing a disease caused by synaptic transmission or release of acetylcholine,

wherein the disease is selected from the group consisting of neuromuscular disorders characterized by skeletal muscle hyperactivity, neuropathic pain, migraine, overactive bladder, rhinitis, sinusitis, acne, dystonia, dystonic contraction, hyperhidrosis, hypersecretion of one or more glands controlled by the cholinergic nervous system, hemifacial spasm, adult-onset spastic torticollis, anal fissure, blepharospasm, cerebral

palsy, cervical dystonia, strabismus, temporomandibular joint disorders and various types of muscle convulsions and spasms.

8. The liquid formulation of claim 2 or 3, for use in reducing the appearance of fine lines and/or wrinkles, enlarging eyes, lifting the corners of mouth, smoothing lines that appear on the upper lip, or relieving muscle tone.

9. The pharmaceutical composition of claim 1, wherein the composition is in a lyophilized form.

10. The aesthetic method of claim 6, wherein the appearance of fine lines and/or wrinkles is on the face.

11. The use of claim 8, wherein the appearance of fine lines and/or wrinkles is on the face.